338 related articles for article (PubMed ID: 15310997)
1. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
2. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
Gleave M; Qian J; Andreou C; Pommerville P; Chin J; Casey R; Steinhoff G; Fleshner N; Bostwick D; Thomas L; Rittmaster R
Prostate; 2006 Nov; 66(15):1674-85. PubMed ID: 16927304
[TBL] [Abstract][Full Text] [Related]
3. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
4. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
5. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
6. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
9. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
10. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
11. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
12. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
14. RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Pitts WR
J Urol; 2005 Apr; 173(4):1433-4; author reply 1434-5. PubMed ID: 15758829
[No Abstract] [Full Text] [Related]
15. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
Shao TC; Li H; Ittmann M; Cunningham GR
J Urol; 2007 Oct; 178(4 Pt 1):1521-7. PubMed ID: 17707058
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
17. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
[TBL] [Abstract][Full Text] [Related]
18. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.
Hahn RG; Fagerström T; Tammela TL; Van Vierssen Trip O; Beisland HO; Duggan A; Morrill B
BJU Int; 2007 Mar; 99(3):587-94. PubMed ID: 17407516
[TBL] [Abstract][Full Text] [Related]
19. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
